-
公开(公告)号：US20230416357A1
公开(公告)日：2023-12-28
申请号：US18253240
申请日：2021-12-06
Applicant: UCB BIOPHARMA SRL
Inventor： Joseph Michael David RASTRICK , John Paul SILVA , Kerry Louise TYSON , Peter Charles ELLIOTT , Seppe Frans Roman LEYSEN , Zainab AHDASH
IPC: C07K16/24
CPC classification number: C07K16/244 , C07K2317/76 , C07K2317/92 , C07K2317/34 , C07K2317/24 , C07K2317/55 , C07K2317/33
Abstract: The present invention relates to antibodies binding to IL22 and inhibiting its interaction with one or more of its natural ligands Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such C are also provided.
-
公开(公告)号：US20230070261A1
公开(公告)日：2023-03-09
申请号：US17759988
申请日：2021-02-01
Applicant: UCB BIOPHARMA SRL
Inventor： Neesha DEDI , Peter Charles ELLIOTT , Seppe Frans Roman LEYSEN , Sean MASON , David James MCMILLAN , Gillian Claire NESS , Niccolo PENGO , Martin Anthony REDHEAD , Alison TURNER , Kerry Louise TYSON
IPC: C07K16/40
Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory anti-KLK5 antibodies and their use in the treatment of Netherton disease, atopic dermatitis and cancer.
-
公开(公告)号：US20240067758A1
公开(公告)日：2024-02-29
申请号：US18255213
申请日：2021-12-06
Applicant: UCB BIOPHARMA SRL
Inventor： Joseph Michael David RASTRICK , John Paul SILVA , Daniel John LIGHTWOOD , Ralph ADAMS , Roger Thomas PALFRAMAN , Kerry Louise TYSON , Peter Charles ELLIOTT , Seema MAYANK , Andrea Julie CROSBY , Emily Mary Cairistine BARRY , Seppe Frans Roman LEYSEN , Zainab AHDASH
CPC classification number: C07K16/468 , C12N15/63 , A61P17/00 , C07K2317/31 , C07K2317/76 , C07K2317/565 , C07K2317/55 , C07K2317/622 , C07K2317/14
Abstract: The present invention relates to antibodies binding to IL13 and IL22. The invention provides novel multi-specific antibodies that bind to both IL13 and IL22 and compositions comprising an antibody that binds to IL13 and an antibody that binds to IL22. The invention further relates to therapeutic uses of the combination of anti-IL13 and anti-IL22 antibodies and multi-specific antibodies that bind to both IL13 and IL22.
-
公开(公告)号：US20230075753A1
公开(公告)日：2023-03-09
申请号：US17759986
申请日：2021-02-01
Applicant: UCB BIOPHARMA SRL
Inventor： Neesha DEDI , Peter Charles ELLIOTT , Seppe Frans Roman LEYSEN , Sean MASON , David James MCMILLAN , Gillian Claire NESS , Niccolo PENGO , Martin Anthony REDHEAD , Alison TURNER , Kerry Louise TYSON
Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory antibodies binding KLK5 and their use in the treatment of Netherton disease, atopic dermatitis and cancer.
-
公开(公告)号：US20230065921A1
公开(公告)日：2023-03-02
申请号：US17821688
申请日：2022-08-23
Applicant: UCB Biopharma SRL
Inventor： Helene Margaret FINNEY , Stephen Edward RAPECKI , Kerry Louise TYSON , Michael John WRIGHT
IPC: C07K16/28 , A01K67/027
Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
-
Patent Agency Ranking
公开(公告)号：US20220220192A1
公开(公告)日：2022-07-14
申请号：US17585174
申请日：2022-01-26
Applicant: UCB BIOPHARMA SRL
Inventor： Ralph ADAMS , Patrick DOWNEY , Terence Seward BAKER , Kerry Louise TYSON , Lorenzo DE LICHTERVELDE , Daniel John LIGHTWOOD , David James MCMILLAN
IPC: C07K16/18
Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
公开(公告)号：US20210101964A1
公开(公告)日：2021-04-08
申请号：US16772043
申请日：2018-12-13
Applicant: UCB Biopharma SRL
Inventor： Patrick DOWNEY , Kerry Louise TYSON , Marco KRIEK , Lorenzo DE LICHTERVELDE , Daniel John LIGHTWOOD , David James MCMILLAN , Peter Charles ELLIOTT , Terence Seward BAKER
Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
公开(公告)号：US20210107971A1
公开(公告)日：2021-04-15
申请号：US16771993
申请日：2018-12-13
Applicant: UCB Biopharma SRL
Inventor： Ralph ADAMS , Patrick DOWNEY , Terence Seward BAKER , Kerry Louise TYSON , Lorenzo DE LICHTERVELDE , Daniel John LIGHTWOOD , David James MCMILLAN
IPC: C07K16/18
Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
公开(公告)号：US20200157215A1
公开(公告)日：2020-05-21
申请号：US16778523
申请日：2020-01-31
Applicant: UCB Biopharma SRL
Inventor： Helene Margaret FINNEY , Stephen Edward RAPECKI , Kerry Louise TYSON , Michael John WRIGHT
IPC: C07K16/28 , A01K67/027
Abstract: The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.
-
公开(公告)号：US20230287134A1
公开(公告)日：2023-09-14
申请号：US18153181
申请日：2023-01-11
Applicant: UCB BIOPHARMA SRL
Inventor： Helene Margaret FINNEY , Stephen Edward RAPECKI , Kerry Louise TYSON , Michael John WRIGHT
CPC classification number: C07K16/289 , C07K16/18 , C07K16/2803 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/24 , C07K2317/76 , C07K2317/90 , C07K2317/35 , C07K2317/64 , C07K2317/624
Abstract: The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.018 seconds)
